Cyagen is attending the GSCN Conference 2026 in Berlin.

Cyagen is a global leader in providing comprehensive solutions for both therapeutic target discovery and pre-clinical validation. We offer end-to-end services that empower the entire workflow, from target validation to pre-clinical research. Our core capabilities combine gene-edited models, AI technology, and a wide range of cross-disciplinary CRO services to accelerate your research and development efforts. We leverage cutting-edge platforms, including the HUGO-GT™ Whole Genome Humanized Model and the HUGO-Ab™ mouse, to provide powerful tools for pre-clinical studies. The HUGO-GT™ model is specifically designed to simulate human gene expression, offering a more relevant and predictive platform for drug efficacy and safety testing. Our expertise spans multiple therapeutic areas, with robust CRO services in Neurological Diseases, Oncology, Metabolic Disorders, Ophthalmology, and Autoimmune Diseases. We also utilize our AI-enabled platforms, including the RDDC Rare Disease Database and the AbSeek™ Antibody Computational Platform, to enhance drug discovery. With a global presence and over 18,760 clients in more than 100 countries, Cyagen is dedicated to providing high-efficiency, full-process solutions that help our partners achieve their research goals.